These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 14645868)

  • 21. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
    Polinski JM; Mohr PE; Johnson L
    Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-utility analysis of the BeSt trial: is a camel in fact a horse with abnormalities in the distribution of dorsal fat? Comment on the article by van den Hout et al.
    Boers M
    Arthritis Rheum; 2009 Nov; 61(11):1616-7; author reply 1617-8. PubMed ID: 19877096
    [No Abstract]   [Full Text] [Related]  

  • 23. Maintaining and optimising anti-TNF therapy.
    Somerville M
    Musculoskeletal Care; 2007 Dec; 5 Suppl 1():1-17. PubMed ID: 18050263
    [No Abstract]   [Full Text] [Related]  

  • 24. It is the best of times; it is the worst of times: is there a way forward? A plethora of treatment options for rheumatoid arthritis, but critical trial design issues.
    O'Dell JR
    Arthritis Rheum; 2007 Dec; 56(12):3884-6. PubMed ID: 18050217
    [No Abstract]   [Full Text] [Related]  

  • 25. Reactions to infliximab in patients with rheumatoid arthritis.
    Prupas M
    J Rheumatol; 2005 Jul; 32(7):1411; author reply 1411. PubMed ID: 15996090
    [No Abstract]   [Full Text] [Related]  

  • 26. Reactions to infliximab in patients with rheumatoid arthritis.
    Sakellariou GT; Chatzigiannis I
    J Rheumatol; 2005 Jul; 32(7):1411-2. PubMed ID: 15996088
    [No Abstract]   [Full Text] [Related]  

  • 27. Anti-tumour necrosis factor therapy in the West Midlands.
    Bartram D; Sheeran T; Price T; Mulherin D
    Rheumatology (Oxford); 2004 Mar; 43(3):400; author reply 400-1. PubMed ID: 14963219
    [No Abstract]   [Full Text] [Related]  

  • 28. Anti-inflammatory inflames Centocor's profits.
    Glaser V
    Nat Biotechnol; 1998 Oct; 16(10):900. PubMed ID: 9788334
    [No Abstract]   [Full Text] [Related]  

  • 29. Now that we know what's BeSt, what is good value for the money?
    Bansback N; Marra CA
    Arthritis Rheum; 2009 Mar; 61(3):289-90. PubMed ID: 19248126
    [No Abstract]   [Full Text] [Related]  

  • 30. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009: comments on the article by M Neovius et al.
    Ohlsson H; Merlo J
    Scand J Rheumatol; 2011 May; 40(3):243-4. PubMed ID: 21529245
    [No Abstract]   [Full Text] [Related]  

  • 31. Costs of rheumatoid arthritis in Hungary.
    Péntek M; Kobelt G; Czirják L; Szekanecz Z; Poór G; Rojkovich B; Polgár A; Genti G; Kiss CG; Brodszky V; Májer I; Gulácsi L
    J Rheumatol; 2007 Jun; 34(6):1437. PubMed ID: 17552071
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed?
    Boers M
    Ann Intern Med; 2009 Nov; 151(9):668-9. PubMed ID: 19884628
    [No Abstract]   [Full Text] [Related]  

  • 33. Dose intensification with infliximab in patients with rheumatoid arthritis.
    Berger A; Edelsberg J; Li TT; Maclean JR; Oster G
    Ann Pharmacother; 2005 Dec; 39(12):2021-5. PubMed ID: 16288073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis.
    van den Bemt BJ; Vos K; den Broeder AA; Blom M; Thurlings RM; Bartelds GM; Stapel SO; Barrera P; Tak PP; Nurmohamed MT; Wolbink GJ
    Ann Rheum Dis; 2009 Aug; 68(8):1368-9. PubMed ID: 19605744
    [No Abstract]   [Full Text] [Related]  

  • 35. PHARMAC responds on TNF inhibitors for inflammatory arthritis.
    Metcalfe S; Moodie P; Grocott R; Wilkinson T
    N Z Med J; 2005 Dec; 118(1227):U1799. PubMed ID: 16372039
    [No Abstract]   [Full Text] [Related]  

  • 36. How to dose infliximab in rheumatoid arthritis: new data on a serious issue.
    van Vollenhoven RF
    Ann Rheum Dis; 2009 Aug; 68(8):1237-9. PubMed ID: 19605741
    [No Abstract]   [Full Text] [Related]  

  • 37. The pharmacoeconomics of newer therapeutics for rheumatic diseases.
    Kavanaugh A
    Rheum Dis Clin North Am; 2006 Feb; 32(1):45-56, viii. PubMed ID: 16504820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infliximab treatment of rheumatoid arthritis.
    Maini SR
    Rheum Dis Clin North Am; 2004 May; 30(2):329-47, vii. PubMed ID: 15172044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference?
    Drummond MF; Barbieri M; Wong JB
    Med Decis Making; 2005; 25(5):520-33. PubMed ID: 16160208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis.
    Hammoudeh M
    Rheumatology (Oxford); 2006 Mar; 45(3):357-9. PubMed ID: 16368727
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.